Randomised clinical trial: a phase 1, dose‐ranging study of the anti‐matrix metalloproteinase‐9 monoclonal antibody GS‐5745 versus placebo for ulcerative colitis

BACKGROUND: Matrix metalloproteinase‐9 is a proteolytic enzyme whose expression is increased in ulcerative colitis. AIM: To evaluate the safety and efficacy of GS‐5745, a fully humanised anti‐matrix metalloproteinase‐9 monoclonal antibody, in moderately‐to‐severely active ulcerative colitis. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandborn, W. J., Bhandari, B. R., Fogel, R., Onken, J., Yen, E., Zhao, X., Jiang, Z., Ge, D., Xin, Y., Ye, Z., French, D., Silverman, J. A., Kanwar, B., Subramanian, G. M., McHutchison, J. G., Lee, S. D., Shackelton, L. M., Pai, R. K., Levesque, B. G., Feagan, B. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Randomised Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089609/
https://www.ncbi.nlm.nih.gov/pubmed/27218676
http://dx.doi.org/10.1111/apt.13653

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089609/
https://www.ncbi.nlm.nih.gov/pubmed/27218676
http://dx.doi.org/10.1111/apt.13653

Ejemplares similares